Slideshows Images Quizzes

Metaglip

Last reviewed on RxList: 1/26/2017
Metaglip Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 1/3/2016

Metaglip (glipizide and metformin HCl) is a combination of two oral diabetes medicines for people with type 2 diabetes who do not use daily insulin injections. Metaglip is not for treating type 1 diabetes. The brand name Metaglip is discontinued, but generic versions may be available. Common side effects of Metaglip (glipizide and metformin HCl) include nausea, vomiting, diarrhea, stomach pain or upset, joint or muscle aches pain, headache, dizziness, or cold symptoms (stuffy nose, sneezing, or sore throat).

Dosage of Metaglip is individualized on the basis of both effectiveness and tolerance while not exceeding the maximum recommended daily dose of 20 mg glipizide/2000 mg metformin. Metaglip may interact with furosemide, nifedipine, cimetidine, ranitidine, amiloride, triamterene, digoxin, morphine, procainamide, quinidine, trimethoprim, vancomycin, or ketoconazole, or itraconazole. Hyperglycemia (high blood sugar) may result if you take Metaglip with isoniazid, diuretics, steroids, heart or blood pressure medications, niacin, phenothiazines, thyroid medicines, birth control pills and other hormones, seizure medicines, and diet pills or medicines to treat asthma, colds or allergies. Hypoglycemia (low blood sugar) may result if you take Metaglip with exenatide, probenecid, nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin or other salicylates, sulfa drugs, monoamine oxidase inhibitors (MAOIs), beta-blockers, or other diabetes medications. Tell your doctor all medications and supplements you use. During pregnancy, Metaglip should be used only when prescribed. Insulin treatment may be preferred during pregnancy. If you are using this drug during your pregnancy, your doctor may switch you to insulin at least 1 month before the expected delivery date because of Metaglip's risk of low blood sugar in your newborn. Consult your doctor and follow your doctor's instructions. This drug passes into breast milk and could have undesirable effects on a nursing infant. Consult your doctor before breastfeeding.

Our Metaglip (glipizide and metformin HCl) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Metaglip Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

This medication may cause lactic acidosis (a build-up of lactic acid in the body, which can be fatal). Lactic acidosis can start slowly and get worse over time. Get emergency medical help if you have even mild symptoms of lactic acidosis, such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, slow or uneven heart rate, dizziness, or feeling very weak or tired.

Stop taking this medication and call your doctor at once if you have a serious side effect such as:

  • feeling short of breath, even with mild exertion, swelling or rapid weight gain;
  • pain or burning with urination;
  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).

Less serious side effects may include:

  • cold symptoms such as stuffy nose, sneezing, sore throat;
  • headache, dizziness;
  • mild nausea, vomiting, diarrhea, stomach pain; or
  • joint or muscle pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Metaglip (Glipizide and Metformin)

Metaglip Professional Information

SIDE EFFECTS

Metaglip (glipizide and metformin)

In a double-blind 24-week clinical trial involving METAGLIP (glipizide and metformin) as initial therapy, a total of 172 patients received METAGLIP (glipizide and metformin) 2.5 mg/250 mg, 173 received METAGLIP (glipizide and metformin) 2.5 mg/500 mg, 170 received glipizide, and 177 received metformin. The most common clinical adverse events in these treatment groups are listed in Table 4.

Table 4: Clinical Adverse Events > 5% in any Treatment Group, by Primary Term, in Initial Therapy Study

Adverse Event Number (%) of Patients
Glipizide 5 mg tablets
N=170
Metformin 500 mg tablets
N=177
METAGLIP 2.5 mg/250 mg tablets
N=172
METAGLIP 2.5 mg/500 mg tablets
N=173
Upper respiratory infection 12 (7.1) 15 (8.5) 17 (9.9) 14 (8.1)
Diarrhea 8 (4.7) 15 (8.5) 4 (2.3) 9 (5.2)
Dizziness 9 (5.3) 2 (1.1) 3 (1.7) 9 (5.2)
Hypertension 17 (10.0) 10 (5.6) 5 (2.9) 6 (3.5)
Nausea/vomiting 6 (3.5) 9 (5.1) 1 (0.6) 3 (1.7)

In a double-blind 18-week clinical trial involving METAGLIP (glipizide and metformin) as second-line therapy, a total of 87 patients received METAGLIP (glipizide and metformin) , 84 received glipizide, and 75 received metformin. The most common clinical adverse events in this clinical trial are listed in Table 5.

Table 5: Clinical Adverse Events > 5% in any Treatment Group, by Primary Term, in Second- Line Therapy Study

Adverse Event Number (%) of Patients
Glipizide 5 mg tabletsa
N=84
Metformin 500 mg tabletsa
N=75
METAGLIP 5 mg/500 mg tabletsa
N=87
Diarrhea 11 (13.1) 13 (17.3) 16 (18.4)
Headache 5 (6.0) 4 (5.3) 11 (12.6)
Upper respiratory infection 11 (13.1) 8 (10.7) 9 (10.3)
Musculoskeletal pain 6 (7.1) 5 (6.7) 7 (8.0)
Nausea/vomiting 5 (6.0) 6 (8.0) 7 (8.0)
Abdominal pain 7 (8.3) 5 (6.7) 5 (5.7)
UTI 4 (4.8) 6 (8.0) 1 (1.1)
a The dose of glipizide was fixed at 30 mg daily; doses of metformin and METAGLIP were titrated.

 Hypoglycemia

In a controlled initial therapy trial of METAGLIP (glipizide and metformin) 2.5 mg/250 mg and 2.5 mg/500 mg the numbers of patients with hypoglycemia documented by symptoms (such as dizziness, shakiness, sweating, and hunger) and a fingerstick blood glucose measurement ≤ 50 mg/dL were 5 (2.9%) for glipizide, 0 (0%) for metformin, 13 (7.6%) for METAGLIP (glipizide and metformin) 2.5 mg/250 mg, and 16 (9.3%) for METAGLIP (glipizide and metformin) 2.5 mg/500 mg. Among patients taking either METAGLIP (glipizide and metformin) 2.5 mg/250 mg or METAGLIP (glipizide and metformin) 2.5 mg/500 mg, 9 (2.6%) patients discontinued METAGLIP (glipizide and metformin) due to hypoglycemic symptoms and 1 required medical intervention due to hypoglycemia. In a controlled second-line therapy trial of METAGLIP (glipizide and metformin) 5 mg/500 mg, the numbers of patients with hypoglycemia documented by symptoms and a fingerstick blood glucose measurement ≤ 50 mg/dL were 0 (0%) for glipizide, 1 (1.3%) for metformin, and 11 (12.6%) for METAGLIP (glipizide and metformin) . One (1.1%) patient discontinued METAGLIP (glipizide and metformin) therapy due to hypoglycemic symptoms and none required medical intervention due to hypoglycemia. (See PRECAUTIONS.)

Gastrointestinal Reactions

Among the most common clinical adverse events in the initial therapy trial were diarrhea and nausea/vomiting; the incidences of these events were lower with both METAGLIP (glipizide and metformin) dosage strengths than with metformin therapy. There were 4 (1.2%) patients in the initial therapy trial who discontinued METAGLIP (glipizide and metformin) therapy due to gastrointestinal (GI) adverse events. Gastrointestinal symptoms of diarrhea, nausea/vomiting, and abdominal pain were comparable among METAGLIP (glipizide and metformin) , glipizide and metformin in the second-line therapy trial. There were 4 (4.6%) patients in the second-line therapy trial who discontinued METAGLIP (glipizide and metformin) therapy due to GI adverse events.

Glipizide

Gastrointestinal Reactions

Cholestatic and hepatocellular forms of liver injury accompanied by jaundice have been reported rarely in association with glipizide; METAGLIP (glipizide and metformin) should be discontinued if this occurs.

Read the entire FDA prescribing information for Metaglip (Glipizide and Metformin)

Related Resources for Metaglip

Related Drugs

Read the Metaglip User Reviews »

© Metaglip Patient Information is supplied by Cerner Multum, Inc. and Metaglip Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors